La neuropatía inducida por quimioterapia (NIQ) es la complicación neurológica más frecuente en el paciente onco-hematológico^1-5.

• Numerosos agentes antineoplásicos empleados en población adulta pueden inducir neuropatía periférica durante el tratamiento^1-5

El diagnóstico de la neuropatía inducida por quimioterapia es principalmente clínico apoyado por exploraciones complementarias^1,6,7.

Brentuximab vedotina provoca tres tipos de neuropatía periférica por afectación de los diferentes tipos de fibras nerviosas^8-18.

• NP Sensitiva^8-10
• NP Motora^8-13
• NP Autonomica^8,14,15,18

La neuropatía periférica puede aparecer durante el tratamiento con brentuximab vedotina, habitualmente como consecuencia de la exposición acumulada^14,16,19-22.

La neuropatía periférica inducida por brentuximab vedotina es manejable mediante modificación de dosis²³.

En estudios de vida real se ha podido observar que la mayoría de los casos de neuropatía provocada por brentuximab vedotina en monoterapia fueron de intensidad leve y reversible con un manejo adecuado de la misma^24,25.

1. Velasco R, Bruna J. Chemotherapy-induced peripheral neuropathy: An unresolved issue. Neurol (Engl Ed). 2010;25(2):116–31. Disponible en: http://dx.doi.org/10.1016/s2173-5808(10)70022-5
2. Velasco R, Alemany M, Villagrán M, Argyriou AA. Predictive biomarkers of oxaliplatin-induced peripheral neurotoxicity. J Pers Med. 2021;11(7):669. Disponible en: http://dx.doi.org/10.3390/jpm11070669
3. Smith EML, Kuisell C, Cho Y, Kanzawa-Lee GA, Gilchrist LS, Park SB, et al. Characteristics and patterns of pediatric chemotherapy-induced peripheral neuropathy: A systematic review. Cancer Treat Res Commun. 2021;28(100420):100420. Disponible en: http://dx.doi.org/10.1016/j.ctarc.2021.100420
4. Velasco R, Alberti P, Bruna J, Psimaras D, Argyriou AA. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment. J Peripher Nerv Syst. 2019;24 (supl 2):S52–62. Disponible en: http://dx.doi.org/10.1111/jns.12338
5. Argyriou AA, Bruna J, Mantovani E, Tamburin S. Neuromuscular complications of cancer therapy. Curr Opin Neurol. 2021;34(5):658–68. Disponible en: http://dx.doi.org/10.1097/WCO.0000000000000969
6. Li T, Timmins HC, Lazarus HM, Park SB. Peripheral neuropathy in hematologic malignancies - Past, present and future. Blood Rev. 2020;43(100653):100653. Disponible en: http://dx.doi.org/10.1016/j.blre.2020.100653
7. Argyriou AA, Park SB, Islam B, Tamburin S, Velasco R, Alberti P, et al. Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. J Neurol Neurosurg Psychiatry. 2019;90(12):1361–9. Disponible en: http://dx.doi.org/10.1136/jnnp-2019-320969
8. Mariotto S, Tecchio C, Sorio M, Bertolasi L, Turatti M, Tozzi MC, et al. Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy. Leuk Lymphoma. 2019;60(11):2806–9. Disponible en: http://dx.doi.org/10.1080/10428194.2019.1605068
9. Fargeot G, Dupel-Pottier C, Stephant M, Lazarovici J, Thomas L, Mouthon-Reignier C, et al. Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies. J Neurol Neurosurg Psychiatry. 2020;91(7):786–8. Disponible en: http://dx.doi.org/10.1136/jnnp-2020-323124
10. Velasco R, Domingo-Domenech E, Sureda A. Brentuximab-induced peripheral neurotoxicity: A multidisciplinary approach to manage an emerging challenge in Hodgkin lymphoma therapy. Cancers (Basel). 2021;13(23):6125. Disponible en: http://dx.doi.org/10.3390/cancers13236125
11. Mariotto S, Ferrari S, Sorio M, Benedetti F, Tridente G, Cavallaro T, et al. Brentuximab vedotin: axonal microtubule’s Apollyon. Blood Cancer J. 2015;5(8):e343. Disponible en: http://dx.doi.org/10.1038/bcj.2015.72
12. Stone JB, DeAngelis LM. Cancer-treatment-induced neurotoxicity--focus on newer treatments. Nat Rev Clin Oncol. 2016;13(2):92–105. Disponible en: http://dx.doi.org/10.1038/nrclinonc.2015.152
13. Pastorelli F, Derenzini E, Plasmati R, Pellegrini C, Broccoli A, Casadei B, et al. Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2013;54(10):2318–21. Disponible en: http://dx.doi.org/10.3109/10428194.2013.773997
14. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–9. Disponible en: http://dx.doi.org/10.1200/JCO.2011.38.0410
15. Clarivet B, Vincent L, Vergely L, Bres V, Foglia K, Cartron G, et al. Adverse reactions related to brentuximab vedotin use: A real-life retrospective study. Therapie. 2019;74(3):343–6. Disponible en: http://dx.doi.org/10.1016/j.therap.2018.07.004
16. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–62. Disponible en: http://dx.doi.org/10.1016/S0140-6736(15)60165-9
17. Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7(1):24. Disponible en: http://dx.doi.org/10.1186/1756-8722-7-24
18. Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126(26):2798–804. Disponible en: http://dx.doi.org/10.1182/blood-2015-06-644336
19. Corbin ZA, Nguyen-Lin A, Li S, Rahbar Z, Tavallaee M, Vogel H, et al. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome. J Neurooncol. 2017;132(3):439–46. Disponible en: http://dx.doi.org/10.1007/s11060-017-2389-9
20. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6. Disponible en: http://dx.doi.org/10.1200/JCO.2011.38.0402
21. Fukuhara N, Yamamoto G, Tsujimura H, Chou T, Shibayama H, Yanai T, et al. Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study. Leuk Lymphoma. 2020;61(1):176–80. Disponible en: http://dx.doi.org/10.1080/10428194.2019.1654100
22. Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, et al. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. Eur J Cancer. 2020;133:120–30. Disponible en: http://dx.doi.org/10.1016/j.ejca.2020.04.010
23. Ficha técnica de Adcetris®. Junio 2022 [consultado marzo 2023]. Disponible en https://www.ema.europa.eu/en/documents/product-information/Adcetris-epar-product-information_es.pdf  
24. Plattel WJ, Bergamasco A, Trinchese F, Gavini F, Bent-Ennakhil N, Zomas A, et al. Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2021;62(14):3320–32. Disponible en: http://dx.doi.org/10.1080/10428194.2021.1957865
25. Pellegrini C, Broccoli A, Pulsoni A, Rigacci L, Patti C, Gini G, et al. Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma. Oncotarget. 2017;8(53):91703–10. Disponible en: http://dx.doi.org/10.18632/oncotarget.18114

▼ Este medicamento está sujeto a seguimiento adicional, es prioritaria la notificación de sospechas de reacciones adversas asociadas a este medicamento.

FICHA TÉCNICA DE ADCETRIS^®